Published in Leukemia on July 01, 2010
The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer (2012) 4.97
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood (2011) 2.50
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood (2011) 2.47
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol (2012) 1.56
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia (2014) 1.41
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica (2011) 1.30
Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation. Haematologica (2013) 1.17
Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. J Clin Invest (2013) 1.12
Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One (2012) 1.11
Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms. J Blood Med (2015) 0.97
Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. Exp Hematol Oncol (2015) 0.83
CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2. Haematologica (2012) 0.82
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer J (2011) 0.77
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J (2016) 0.77
Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. Blood (2016) 0.76
Somatic mutations in murine models of leukemia and lymphoma: Disease specificity and clinical relevance. Genes Chromosomes Cancer (2017) 0.75
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol (2009) 4.18
Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia (2009) 2.77
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res (2010) 2.69
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia (2010) 2.23
PCR amplification introduces errors into mononucleotide and dinucleotide repeat sequences. Mol Pathol (2001) 1.67
Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia (2009) 1.45
High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia (2010) 1.38
Improving sequencing quality from PCR products containing long mononucleotide repeats. Biotechniques (2010) 1.35
Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol (1990) 8.97
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet (1999) 6.61
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med (1994) 4.46
Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids (2003) 3.66
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia (2009) 3.49
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia (2009) 3.23
Turnover of bacterial glutamine synthetase: oxidative inactivation precedes proteolysis. Proc Natl Acad Sci U S A (1981) 2.93
Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation (2009) 2.85
Oxidative damage during aging targets mitochondrial aconitase. Proc Natl Acad Sci U S A (1997) 2.76
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia (2010) 2.65
Critical care in the emergency department: a time-based study. Crit Care Med (1993) 2.59
Protein oxidation. Ann N Y Acad Sci (2000) 2.57
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia (2007) 2.49
Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology (1995) 2.48
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut (2010) 2.47
Oxidative modification of glutamine synthetase. I. Inactivation is due to loss of one histidine residue. J Biol Chem (1983) 2.29
Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation (2000) 2.22
PHF6 mutations in adult acute myeloid leukemia. Leukemia (2010) 2.20
Heart transplantation for end-stage heart failure due to cardiac sarcoidosis. Transplant Proc (2013) 2.15
Glutamic and aminoadipic semialdehydes are the main carbonyl products of metal-catalyzed oxidation of proteins. Proc Natl Acad Sci U S A (2001) 2.04
Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med (1994) 2.03
The tongue flap in the primary treatment of cleft palate: a report of 19 cases. Br J Plast Surg (1992) 1.95
Development of an electrically stimulated neoanal sphincter. Lancet (1991) 1.91
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia (2011) 1.88
Clinical characteristics of paediatric H1N1 admissions in Birmingham, UK. Lancet (2009) 1.87
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene (2011) 1.87
Mammalian thioredoxin reductase: oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity. Proc Natl Acad Sci U S A (2000) 1.82
Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem (2000) 1.82
Conversion of amino acid residues in proteins and amino acid homopolymers to carbonyl derivatives by metal-catalyzed oxidation reactions. J Biol Chem (1989) 1.80
Development of a highly polymorphic STR marker for identity testing purposes at the human androgen receptor gene (HUMARA). J Forensic Sci (1998) 1.80
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia (2011) 1.79
Oxidative modification of glutamine synthetase. II. Characterization of the ascorbate model system. J Biol Chem (1983) 1.78
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia (2008) 1.78
Is blastocyst transfer useful as an alternative treatment for patients with multiple in vitro fertilization failures? Fertil Steril (1999) 1.76
Identification of oxidant-sensitive proteins: TNF-alpha induces protein glutathiolation. Biochemistry (2000) 1.70
Prediction of adult height from height and bone age in childhood. A new system of equations (TW Mark II) based on a sample including very tall and very short children. Arch Dis Child (1983) 1.69
Purification of a protease from Escherichia coli with specificity for oxidized glutamine synthetase. J Biol Chem (1987) 1.68
Iron-dependent oxidation, ubiquitination, and degradation of iron regulatory protein 2: implications for degradation of oxidized proteins. Proc Natl Acad Sci U S A (1998) 1.66
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia (2009) 1.63
Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. J Biol Chem (1999) 1.63
Cardiac arrest presenting with rhythms other than ventricular fibrillation: contribution of resuscitative efforts toward total survivorship. Crit Care Med (1993) 1.61
Loss of the ataxia-telangiectasia gene product causes oxidative damage in target organs. Proc Natl Acad Sci U S A (1999) 1.57
Demonstration of an osteoblast defect in two cases of human malignant osteopetrosis. Correction of the phenotype after bone marrow transplant. J Clin Invest (1996) 1.57
Metal-catalyzed oxidation of Escherichia coli glutamine synthetase: correlation of structural and functional changes. Arch Biochem Biophys (1990) 1.57
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia (2011) 1.55
Evidence for transhemispheric diaschisis in unilateral stroke. Arch Neurol (1989) 1.54
Oxidative dissociation of human alpha 2-macroglobulin tetramers into dysfunctional dimers. J Biol Chem (1994) 1.53
Randomized, double-blinded, placebo-controlled study of effect of wheat bran fiber and calcium on fecal bile acids in patients with resected adenomatous colon polyps. J Natl Cancer Inst (1996) 1.51
Glucose uptake by gliomas after treatment. A positron emission tomographic study. Arch Neurol (1989) 1.49
Purification and biochemical characterisation of the EcoR124 type I modification methylase. Nucleic Acids Res (1992) 1.48
Plastic surgeon as an ostrich in the surgical treatment of cleft palate. Plast Reconstr Surg (1992) 1.47
Sleep patterns in intensive care unit patients: a study using the bispectral index. Crit Care Resusc (2001) 1.46
Development and evaluation of a PCR method for detection of the Clostridium difficile toxin B gene in stool specimens. J Clin Microbiol (2002) 1.46
Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J Exp Med (1999) 1.45
Dose-dependent vasopressor response to epinephrine during CPR in human beings. Ann Emerg Med (1989) 1.44
Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol (1999) 1.42
Serine protease inhibitor-6 differentially affects the survival of effector and memory alloreactive CD8-T cells. Am J Transplant (2015) 1.41
Use of laparoscopically mobilized peritoneum in the creation of a neovagina. Fertil Steril (2000) 1.39
The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene (2007) 1.39
Characterization of peripheral-type benzodiazepine binding sites in brain using [3H]Ro 5-4864. Mol Pharmacol (1982) 1.38
Post placement. Br Dent J (2013) 1.38
An audit of out of hours interventional vascular radiology. Eur J Vasc Endovasc Surg (2003) 1.38
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) (2002) 1.37
Vimentin: an evaluation of its role as a tumour marker. Histopathology (1987) 1.36
Accuracy of results obtained by performing a second ligase chain reaction assay and PCR analysis on urine samples with positive or near-cutoff results in the LCx test for Chlamydia trachomatis. J Clin Microbiol (2002) 1.35
Calcium-dependent enhancement of depletion-activated calcium current in Jurkat T lymphocytes. J Membr Biol (1996) 1.35
Gunshot injuries to the extremities: experience of a U.K. trauma centre. Injury (2005) 1.35
Pooling cervical swabs and testing by ligase chain reaction are accurate and cost-saving strategies for diagnosis of Chlamydia trachomatis. J Clin Microbiol (2000) 1.34
Sudden cardiac death and antipsychotic drugs: do we know enough? Arch Gen Psychiatry (2001) 1.32
Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem (2001) 1.30
Peroxynitrite-mediated modification of proteins at physiological carbon dioxide concentration: pH dependence of carbonyl formation, tyrosine nitration, and methionine oxidation. Proc Natl Acad Sci U S A (1999) 1.28
Sequence of a peptide susceptible to mixed-function oxidation. Probable cation binding site in glutamine synthetase. J Biol Chem (1986) 1.27
Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci U S A (1988) 1.24
Selectivity of protein oxidative damage during aging in Drosophila melanogaster. Biochem J (2001) 1.24
Phorbol esters inhibit agonist-induced [3H] inositol-1-phosphate accumulation in rat hippocampal slices. Biochem Biophys Res Commun (1984) 1.24
Quantitation of aromatic residues in proteins: model compounds for second-derivative spectroscopy. Biochemistry (1982) 1.24
The AAGL classification system for laparoscopic hysterectomy. Classification committee of the American Association of Gynecologic Laparoscopists. J Am Assoc Gynecol Laparosc (2000) 1.24
Copper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependent and cysteine-independent mechanisms. Proc Natl Acad Sci U S A (1991) 1.24
Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. Br J Cancer (2012) 1.24
A deletion mutant of the type IC restriction endonuclease EcoR1241 expressing a novel DNA specificity. Nucleic Acids Res (1993) 1.22
Age-related decline of rat liver multicatalytic proteinase activity and protection from oxidative inactivation by heat-shock protein 90. Arch Biochem Biophys (1996) 1.22
Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. Free Radic Biol Med (1995) 1.21
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia (2010) 1.20